Evidence map›Paper›PMID 31372697›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism.

Nazila Fathi Maroufi, Vahid Vahedian, Seyed Ali Miresmaeili Mazrakhondi, Wesam Kooti, Hosein Ajami Khiavy, Roya Bazzaz, Fatemeh Ramezani, Seyed Mohammadbagher Pirouzpanah, Marjan Ghorbani, Maryam Akbarzadeh and 3 more

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Nazila Fathi MaroufiStem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Vahid VahedianDepartment of Medical Laboratory Sciences, Faculty of Medicine, Islamic Azad University (IAU), Sari, Iran.
Seyed Ali Miresmaeili MazrakhondiDepartment of Biology, Faculty of Basic Sciences, Yazd University, Yazd, Iran.
Wesam KootiLung Diseases and Allergy Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Hosein Ajami KhiavyStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Roya BazzazStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Fatemeh RamezaniDepartment of Molecular Medicine, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran.
Seyed Mohammadbagher PirouzpanahDepartment of Genetic and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, 34755, Istanbul, Turkey.
Marjan GhorbaniStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Maryam AkbarzadehStem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Hamed HajipourDepartment of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Saeed GhanbarzadehCancer Gene Therapy Research Center, Zanjan University of Medical Science, Zanjan, Iran. ghanbarzadehs@zums.ac.ir.
Mehdi SabzichiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. mehdi.sabzichi@gmail.com.ORCID 0000-0002-5149-1378

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The harmful dose-dependent side effects of chemotherapy drugs have caused the discovery of novel perspective to evaluate chemotherapy protocols. In this study, the potential application of Compritol was investigated as a major scaffold into nanostructured lipid careers to highlight myricetin efficiency in treatment of breast cancer cells along with codelivery of docetaxel (DXT). Characterization of myricetin-loaded NLCs was carried out by measuring the particle size and zeta potential, using the scanning electron microscopy. MTT, DAPI staining, flow cytometric, and RT-PCR (real-time) assays were used to recognize novel formulation behavior on cell cytotoxicity as well as recognizing molecular mechanism of formulation concerning apoptosis phenomenon. Myricetin-loaded NLCs reduced the cell viability from 50 ± 2.3 to 40 ± 1.3% (p < 0.05). Percentage of apoptosis improved with combination treatment of myricetin-loaded NLCs and DXT in the MDA-MBA231 breast cancer cells. Expression of antiapoptotic genes (survivin, Cyclin B1, and Mcl1) indicated a significant reduction in factor along with increment in proapoptotic factor Bax and Bid mRNA rates. Overall, our results represented that the NLC delivery system could be a promising strategy to enhance the effect of anticancer agents such as DXT on breast cancer.

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsCell Line, TumorCell SurvivalDocetaxelDrug CarriersDrug LiberationFatty AcidsFlavonoidsG1 Phase Cell Cycle CheckpointsHumansNanoparticlesAntineoplastic AgentsDocetaxelDrug CarriersFatty AcidsFlavonoidsglyceryl behenatemyricetinApoptosisDocetaxolMyricetinNanostructured lipid carrier (NLC)

Identifiers

PMID31372697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.